A IA pode prever a resposta de um paciente a um antidepressivo em 48 horas após a primeira dose ?

As ferramentas de IA que utilizam a variabilidade da frequência cardíaca, a dilatação da pupila ou os microestados do EEG para prever a eficácia de antidepressivos em dois dias empurram os limites da sensibilidade dos biomarcadores e da inferência causal. A prática clínica atual baseia-se na observação de ensaios que duram semanas. A validação requer ensaios cegos com resultados clínicos de verdade terrestre e limiares estatísticos rigorosos.

Background

Researchers have explored AI tools using heart rate variability, pupil dilation, or EEG microstates to forecast antidepressant efficacy within two days, pushing the limits of biomarker sensitivity and causal inference. Current clinical practice relies on weeks-long trial observation. Validation requires blinded trials with ground-truth clinical outcomes and rigorous statistical thresholds. A 2020 review in the Journal of Clinical Psychopharmacology noted that while AI has shown promise in analyzing large datasets—including genetic information, brain imaging, and clinical variables—the ability to predict response within 48 hours remains in the early stages. Biomarkers tied to changes in brain activity or gene expression have been investigated, yet these findings are preliminary, and more research is needed to develop reliable predictive models. Clinicians still largely depend on trial and error and patient-reported outcomes to assess antidepressant effectiveness. As of May 14, 2026, predicting antidepressant response within 48 hours of the first dose remains an active area of investigation.